Article - 27 Oct 2010
At Oxford Instruments Plasma Technology ave recently optimized the growth procedure to improve structural properties and surface morphology of thick AlN layers deposited via hydride vapor-phase...
Article - 8 Mar 2005
Metal and ceramic matrix composites hold extreme potential for advanced applications such as aerospace. Nanostructuring could further improve material properties. The benefits of nanostructuring are...
Article - 5 Jul 2011
The NanoTest Vantage has unique capabilities that make it ideally suited to use in the automotive sector. It can perform a range of different tests and can work at temperatures up to 750ºC where it...
Article - 5 Dec 2006
Nanoindentation techniques with the Anton Paar Nano Hardness Tester (NHT), has allowed highly localized hardness and modulus measurements to be performed on very small material volumes.
News - 10 Jan 2012
Alnylam Pharmaceuticals, a company specializing in RNAi therapeutics, has announced the submission of a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory...
News - 21 Mar 2012
Alnylam Pharmaceuticals, a company specializing in RNAi therapeutics, has begun the Phase I clinical trial of ALN-TTR02, which uses the company’s in-house second-generation lipid nanoparticle...
News - 31 Aug 2013
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced the publication of two articles in peer-reviewed scientific journals — the Journal...
News - 1 Feb 2013
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that complete study results have been published from a Phase I trial with ALN-VSP,...
News - 14 Jan 2015
Today, we’re surrounded by a variety of electronic devices that are moving increasingly closer to us – we can attach and wear them, or even implant electronics inside our...
News - 2 Jul 2013
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented positive results from its Phase II...